Unknown

Dataset Information

0

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.


ABSTRACT: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice received a Western-type diet and were treated with alirocumab (3 or 10 mg/kg, weekly subcutaneous dosing) alone and in combination with atorvastatin (3.6 mg/kg/d) for 18 weeks. Alirocumab alone dose-dependently decreased total cholesterol (-37%; -46%, P < 0.001) and TGs (-36%; -39%, P < 0.001) and further decreased cholesterol in combination with atorvastatin (-48%; -58%, P < 0.001). Alirocumab increased hepatic LDL receptor protein levels but did not affect hepatic cholesterol and TG content. Fecal output of bile acids and neutral sterols was not changed. Alirocumab dose-dependently decreased atherosclerotic lesion size (-71%; -88%, P < 0.001) and severity and enhanced these effects when added to atorvastatin (-89%; -98%, P < 0.001). Alirocumab reduced monocyte recruitment and improved the lesion composition by increasing the smooth muscle cell and collagen content and decreasing the macrophage and necrotic core content. Alirocumab dose-dependently decreases plasma lipids and, as a result, atherosclerosis development, and it enhances the beneficial effects of atorvastatin in APOE*3Leiden.CETP mice. In addition, alirocumab improves plaque morphology.

SUBMITTER: Kuhnast S 

PROVIDER: S-EPMC4174003 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.

Kühnast Susan S   van der Hoorn José W A JW   Pieterman Elsbet J EJ   van den Hoek Anita M AM   Sasiela William J WJ   Gusarova Viktoria V   Peyman Anusch A   Schäfer Hans-Ludwig HL   Schwahn Uwe U   Jukema J Wouter JW   Princen Hans M G HM  

Journal of lipid research 20140819 10


Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of alirocumab in APOE*3Leiden.CETP mice. Mice received a Western-type diet and were treated with alirocumab (3 or 10 mg/kg, weekly subcutaneous dosing) alone and in combination with atorvastatin (3.6 mg/kg/d) for 18 weeks. Alirocumab alone dose-dependen  ...[more]

Similar Datasets

| S-EPMC4820828 | biostudies-literature
| S-EPMC4677302 | biostudies-literature
| S-EPMC7053846 | biostudies-literature
| S-EPMC4001802 | biostudies-literature
| S-EPMC3338496 | biostudies-literature
| S-EPMC5869115 | biostudies-literature
| S-EPMC8978048 | biostudies-literature
| S-EPMC9963243 | biostudies-literature
| S-EPMC4974561 | biostudies-other
| S-EPMC3089705 | biostudies-literature